Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.36 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.36 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.36 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL958612 | 0.84 | CXCR2 (0.46) | CXCR2HPGDKDM4EALDH1A1KAT6A | |
| SCHEMBL957633 | 0.84 | CXCR2 (0.52) | CXCR2HPGDKDM4EALDH1A1HSD17B10 | |
| SCHEMBL955463 | 0.77 | CXCR2 (0.42) | CXCR2HPGDKDM4EALDH1A1HSD17B10 | |
| SCHEMBL959542 | 0.77 | CXCR2 (0.52) | CXCR2HPGDKDM4EALDH1A1HSD17B10 | |
| SCHEMBL956296 | 0.75 | CXCR2 (0.56) | CXCR2GAA | |
| SCHEMBL956726 | 0.74 | CXCR2 (0.53) | CXCR2 | |
| SCHEMBL959381 | 0.74 | CXCR2 (0.51) | CXCR2 | |
| SCHEMBL956304 | 0.74 | CXCR2 (0.72) | CXCR2 | |
| SCHEMBL958516 | 0.74 | CXCR2 (0.54) | CXCR2ALDH1A1 | |
| SCHEMBL956581 | 0.74 | CXCR2 (0.57) | CXCR2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009429-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | NOVARTIS AG (CH) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009429-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885PTGS2 236/4885PTGS1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.